Regulus Therapeutics
RGLS
#7340
Rank
NZ$1.00 B
Marketcap
NZ$14.54
Share price
0.00%
Change (1 day)
447.47%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -NZ$79.77 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -NZ$82.33 Million a decrease over its 2023 earnings that were of -NZ$52.45 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -NZ$79.77 Million-3.1%
2024 -NZ$82.33 Million56.97%
2023 -NZ$52.45 Million6.51%
2022 -NZ$49.25 Million2.53%
2021 -NZ$48.03 Million93.59%
2020 -NZ$24.81 Million-15.41%
2019 -NZ$29.33 Million-64.46%
2018 -NZ$82.51 Million-33.26%
2017 -NZ$0.13 Billion-13.98%
2016 -NZ$0.15 Billion44.77%
2015 -NZ$99.28 Million-1.63%
2014 -NZ$0.11 Billion203.6%
2013 -NZ$33.25 Million8.65%
2012 -NZ$30.6 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
NZ$12.75 B-15,196.86%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
NZ$1.80 B-2,232.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$21.22 B-25,211.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$25.53 B-30,317.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$14.05 B-16,734.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-NZ$0.2 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-NZ$0.21 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$2.00 B-2,471.21%๐Ÿ‡บ๐Ÿ‡ธ USA